Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population

E. Ciruelos; G. Jerusalem; M. Martin; V. C. G. Tjan-Heijnen; P. Neven; J. Gavila; F. Montemurro; D. Generali; I. Lang; M. J. Martinez-Serrano; M. F. Perello; P. Conte

doi:10.1007/s12094-020-02327-5

Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population

E. Ciruelos^*, G. Jerusalem, M. Martin, V. C. G. Tjan-Heijnen, P. Neven, J. Gavila, F. Montemurro, D. Generali, I. Lang, M. J. Martinez-Serrano, M. F. Perello, P. Conte

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	1857-1866
Number of pages	10
Journal	Clinical & Translational Oncology
Volume	22
Issue number	10
DOIs	https://doi.org/10.1007/s12094-020-02327-5
Publication status	Published - Oct 2020

Keywords

Aromatase inhibitors
Breast neoplasm
Endocrine therapy
Everolimus
Post-menopausal women
Targeted therapy
PLACEBO-CONTROLLED TRIAL
ENDOCRINE THERAPY
POSTMENOPAUSAL WOMEN
DOUBLE-BLIND
SINGLE-ARM
FULVESTRANT
RESISTANCE
SAFETY
MULTICENTER
PALBOCICLIB

Access to Document

10.1007/s12094-020-02327-5

Cite this

Ciruelos, E., Jerusalem, G., Martin, M., Tjan-Heijnen, V. C. G., Neven, P., Gavila, J., Montemurro, F., Generali, D., Lang, I., Martinez-Serrano, M. J., Perello, M. F., & Conte, P. (2020). Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population. Clinical & Translational Oncology, 22(10), 1857-1866. https://doi.org/10.1007/s12094-020-02327-5

Ciruelos, E. ; Jerusalem, G. ; Martin, M. ; Tjan-Heijnen, V. C. G. ; Neven, P. ; Gavila, J. ; Montemurro, F. ; Generali, D. ; Lang, I. ; Martinez-Serrano, M. J. ; Perello, M. F. ; Conte, P. / Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer : incidence and time course of adverse events in the phase IIIb BALLET population. In: Clinical & Translational Oncology. 2020 ; Vol. 22, No. 10. pp. 1857-1866.

@article{fcc1b0434bbb4593a4c8f68dc6ca87e1,

title = "Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population",

keywords = "Aromatase inhibitors, Breast neoplasm, Endocrine therapy, Everolimus, Post-menopausal women, Targeted therapy, PLACEBO-CONTROLLED TRIAL, ENDOCRINE THERAPY, POSTMENOPAUSAL WOMEN, DOUBLE-BLIND, SINGLE-ARM, FULVESTRANT, RESISTANCE, SAFETY, MULTICENTER, PALBOCICLIB",

author = "E. Ciruelos and G. Jerusalem and M. Martin and Tjan-Heijnen, {V. C. G.} and P. Neven and J. Gavila and F. Montemurro and D. Generali and I. Lang and Martinez-Serrano, {M. J.} and Perello, {M. F.} and P. Conte",

year = "2020",

month = oct,

doi = "10.1007/s12094-020-02327-5",

language = "English",

volume = "22",

pages = "1857--1866",

journal = "Clinical & Translational Oncology",

issn = "1699-048X",

publisher = "Springer",

number = "10",

}

Ciruelos, E, Jerusalem, G, Martin, M, Tjan-Heijnen, VCG, Neven, P, Gavila, J, Montemurro, F, Generali, D, Lang, I, Martinez-Serrano, MJ, Perello, MF & Conte, P 2020, 'Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population', Clinical & Translational Oncology, vol. 22, no. 10, pp. 1857-1866. https://doi.org/10.1007/s12094-020-02327-5

Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer : incidence and time course of adverse events in the phase IIIb BALLET population. / Ciruelos, E.; Jerusalem, G.; Martin, M.; Tjan-Heijnen, V. C. G.; Neven, P.; Gavila, J.; Montemurro, F.; Generali, D.; Lang, I.; Martinez-Serrano, M. J.; Perello, M. F.; Conte, P.

In: Clinical & Translational Oncology, Vol. 22, No. 10, 10.2020, p. 1857-1866.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer

T2 - incidence and time course of adverse events in the phase IIIb BALLET population

AU - Ciruelos, E.

AU - Jerusalem, G.

AU - Martin, M.

AU - Tjan-Heijnen, V. C. G.

AU - Neven, P.

AU - Gavila, J.

AU - Montemurro, F.

AU - Generali, D.

AU - Lang, I.

AU - Martinez-Serrano, M. J.

AU - Perello, M. F.

AU - Conte, P.

PY - 2020/10

Y1 - 2020/10

KW - Aromatase inhibitors

KW - Breast neoplasm

KW - Endocrine therapy

KW - Everolimus

KW - Post-menopausal women

KW - Targeted therapy

KW - PLACEBO-CONTROLLED TRIAL

KW - ENDOCRINE THERAPY

KW - POSTMENOPAUSAL WOMEN

KW - DOUBLE-BLIND

KW - SINGLE-ARM

KW - FULVESTRANT

KW - RESISTANCE

KW - SAFETY

KW - MULTICENTER

KW - PALBOCICLIB

U2 - 10.1007/s12094-020-02327-5

DO - 10.1007/s12094-020-02327-5

M3 - Article

VL - 22

SP - 1857

EP - 1866

JO - Clinical & Translational Oncology

JF - Clinical & Translational Oncology

SN - 1699-048X

IS - 10

ER -

Ciruelos E, Jerusalem G, Martin M, Tjan-Heijnen VCG, Neven P, Gavila J et al. Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population. Clinical & Translational Oncology. 2020 Oct;22(10):1857-1866. https://doi.org/10.1007/s12094-020-02327-5